Whitnell & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Whitnell & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$12K	Buy	+4,100	New	+$10.7K	﹤0.01%	254

Other funds holding BMY.RT

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Whitnell & Co's BMY.RT Position: Q4 2019 in Review

Whitnell & Co opened a new position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2019: 4,100 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #254 among its holdings.

616 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2019.

Whitnell & Co held 4,100 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $12K as of Q4 2019.
Bristol-Myers Squibb Company Contingent Value Rights was a new Whitnell & Co position in Q4 2019.
Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Whitnell & Co's portfolio in Q4 2019, its #254 holding.
616 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2019.

Based on Whitnell & Co's 13F filing for Q4 2019, filed 11 Feb 2020.